Axsome Therapeutics: Engaging the Investment Community
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a pioneering biopharmaceutical enterprise focused on revolutionary treatments for central nervous system (CNS) disorders, has exciting plans ahead as it prepares to engage with investors at significant upcoming conferences. This engagement highlights the company's commitment to advancing the conversation about its innovative treatment approaches and pipeline advancements.
Upcoming Conference Participation
During the month of December, Axsome will actively participate in notable investor conferences. Here’s what investors can look forward to:
Piper Sandler Annual Healthcare Conference
The Piper Sandler 37th Annual Healthcare Conference is a prominent event where key players in the healthcare sector congregate to discuss investment opportunities. Axsome’s fireside chat is scheduled for Wednesday, December 3, 2025, at 4:00 p.m. ET. This session aims to shed light on their strategic initiatives and advancements in CNS therapies.
BofA Securities CNS Therapeutics Virtual Conference
Another critical gathering is the BofA Securities CNS Therapeutics Virtual Conference, where Axsome will showcase its innovative portfolio on Monday, December 8, 2025, at 11:40 a.m. ET. This virtual setting presents an excellent opportunity for stakeholders to gain insight into the company’s vision and progress.
Accessing the Webcasts
For those interested in following these discussions, a live webcast of the presentation during the Piper Sandler conference will be available on the Axsome website. Attendees can access the "Webcasts & Presentations" section in the "Investors" area. Additionally, a replay of the webcast will be available for approximately 30 days post-event, ensuring that all interested parties have an opportunity to engage with the content.
About Axsome Therapeutics
Axsome Therapeutics stands at the forefront of biopharmaceutical innovation, particularly in the treatment of serious CNS conditions. The company is recognized for its commitment to developing groundbreaking therapies aimed at filling critical gaps within patient care. Their diverse portfolio includes FDA-approved treatments for significant conditions such as major depressive disorder, narcolepsy, obstructive sleep apnea, and migraine, alongside several other developmental programs targeting widespread neurological and psychiatric issues affecting millions across the nation.
Contact Information
For inquiries related to investment opportunities, reach out to:
Ashley Dong
Director, Investor Relations
(929) 687-1614
adong@axsome.com
Media inquiries can be directed to:
Darren Opland
Senior Director, Corporate Communications
(929) 837-1065
dopland@axsome.com
Frequently Asked Questions
What is Axsome Therapeutics focusing on in the upcoming conferences?
Axsome Therapeutics is set to showcase its innovative pipeline and engage investors in discussions about their advancements in CNS disorder treatments.
When will Axsome's fireside chats take place?
The fireside chats are scheduled for December 3 and December 8, 2025, during two prominent healthcare conferences.
How can one access the webcasts of Axsome's presentations?
Webcasts can be accessed via the "Webcasts & Presentations" section found in the investors' area of Axsome's official website.
What types of disorders does Axsome Therapeutics target?
Axsome focuses on treating serious CNS disorders, including depression, narcolepsy, obstructive sleep apnea, and migraine.
Who should I contact for investor relations at Axsome Therapeutics?
Ashley Dong, the Director of Investor Relations, is the primary contact for any investor-related inquiries.